Catalog_No	Drug Name/ Product Name	CAS	Product Line	Target	Path	Area	Citation
HY-13948	Angiotensin II human	4474-91-3	Peptides	Angiotensin Receptor; Apoptosis	Apoptosis; GPCR/G Protein	Cardiovascular Disease; Endocrinology; Cancer	[A1] [A2] [A3] [A4] [A5]
HY-P0035	Insulin (human)	11061-68-0	Peptides	Insulin Receptor	Protein Tyrosine Kinase/RTK	Metabolic Disease; Endocrinology	[B1] [B2]
HY-W002300	Boc-L-Valine	13734-41-3	Peptides	Amino Acid Derivatives			[C1]
HY-W009970	Ethyl 2-(benzylamino)acetate	6436-90-4	Peptides	Others			[D1]
HY-13948	Angiotensin II human	4474-91-3	Peptides	Angiotensin Receptor; Apoptosis	Apoptosis; GPCR/G Protein	Cardiovascular Disease; Endocrinology; Cancer	[E1] [E2] [E3] [E4] [E5]
HY-P1731B	Tirzepatide (hydrochloride)		Peptides	GCGR	GPCR/G Protein	Metabolic Disease	[F1]

---

[A1]. de Gasparo M, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000 Sep;52(3):415-72.
[A2]. Fyhrquist F, et al. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995 Nov;9 Suppl 5:S19-24.
[A3]. Hu C, et al. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway. Hypertension. 2007;50(5):952-957.
[A4]. Nabah YN, et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation. 2004;110(23):3581-3586.
[A5]. Crowley SD, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17985-90."

---

[B1]. Bell GI, et al. Sequence of the human insulin gene. Nature. 1980 Mar 6;284(5751):26-32.
[B2]. Tseng CH, et al. Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes. BMC Cancer. 2015 Nov 4;15:846.

---

[C1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.

---

[D1]. Jason Mccartney, et al. Modulators of cystic fibrosis transmembrane conductance regulator. Patent WO2022076625A1.

---

[E1]. de Gasparo M, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000 Sep;52(3):415-72.
[E2]. Fyhrquist F, et al. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995 Nov;9 Suppl 5:S19-24.
[E3]. Hu C, et al. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway. Hypertension. 2007;50(5):952-957.
[E4]. Nabah YN, et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation. 2004;110(23):3581-3586.
[E5]. Crowley SD, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17985-90.

---

[F1]. Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193.